C

Corvus Pharmaceuticals

D

CRVS

USD

0.07

(1.275%)

Market Closed

10,437.00

حجم التداول

-0.43

الربح لكل سهم

-

العائد الربحي

-12.930233

P/E

347,785,122.36

حجم السوق

اليوم

1.2750%

1 اسبوع

9.020%

1 شهر

32.067%

6 اشهر

182.234%

12 اشهر

251.899%

بداية السنة

221.387%

كل الوقت

0%

أصول ذات صلة

Title:
Corvus Pharmaceuticals

Sector:

Healthcare

Industry:

Biotechnology

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

هل تحتاج مساعدة او لديك استفسار؟

تواصل معنا